Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 49Nivolumab 21Cisplatin 11Cetuximab 11Carboplatin 10Paclitaxel 8Gemcitabine 8Docetaxel 8atezolizumab 7Ipilimumab 7Cyclophosphamide 7spartalizumab 6durvalumab 6Fluorouracil 6Capecitabine 6fludarabine 5avelumab 5Albumin-Bound Paclitaxel 5cemiplimab 4Trastuzumab 4Taxes 4Oxaliplatin 4Leucovorin 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3tisotumab vedotin 3aldesleukin 3Specimen Handling 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × SGN-LIV1A × Gastrointestinal × Clear all
NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 2 Terminated
205 enrolled 54 charts
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡